Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27402285 | 0.85 | CYP1A2 (0.48) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL28014632 | 0.85 | CYP1A2 (0.48) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL4065530 | 0.85 | CYP1A2 (0.48) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL6263374 | 0.85 | CYP1A2 (0.53) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL19688524 | 0.85 | CYP1A2 (0.53) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL6664822 | 0.82 | CYP3A4 (0.49) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL9829481 | 0.80 | CYP1A2 (0.49) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL372069 | 0.80 | CYP1A2 (0.44) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL29800505 | 0.80 | CYP1A2 (0.44) | CYP1A2MGAMPDGFRBPDGFRANQO1 | |
| SCHEMBL30474837 | 0.80 | CYP1A2 (0.52) | CYP1A2MGAMPDGFRBPDGFRANQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4724337-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-20060128962-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ALLEN MICHAEL S | 2006-06-15 | — | — | US | claimed |
| US-20030199696-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2003-10-23 | — | — | US | claimed |
| JP-2003503388-A | — | — | 2003-01-28 | — | — | JP | claimed |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-11-07 | — | — | US | claimed |
| EP-1192139-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | Abbott Laboratories (US) | 2002-04-03 | — | — | EP | claimed |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | claimed |
| EP-2409964-A2 | Preparation of substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2261212-A2 | Preparation of quinoline-substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128962-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | CYP1A2 47/4885MGAM 16/4885PDGFRB 4477/4885 |
| US-20030199696-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | CYP1A2 47/4885MGAM 16/4885PDGFRB 4477/4885 |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | CYP1A2 47/4885MGAM 16/4885PDGFRB 4477/4885 |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | CYP1A2 47/4885MGAM 16/4885PDGFRB 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.